
|Articles|April 1, 2002
Infliximab finds utility in management of pyoderma gangrenosum
New Orleans - The experiences of an expanding series of patients indicate infliximab (Remicade) is a valuable therapy for the management of pyoderma gangrenosum (PG), Marketa Limova, M.D., said at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Top 5 Articles of the Week: November 30-December 5
3
The Weekly Roundup: December 1-5
4
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
5



















